Corporate GovernanceApr 30, 2026, 06:23 AM
LTRN Reprices Executive & Director Stock Options to $5.04
AI Summary
Lantern Pharma Inc. filed an Amendment No. 1 to its 2025 Form 10-K to include previously omitted information regarding Part III, Items 10-14. The amendment details executive and director compensation, corporate governance, and security ownership. A key update includes a one-time stock option repricing for certain outstanding options, adjusting their exercise price to $5.04 per share, conditional on continued service.
Key Highlights
- Stock options repriced to $5.04/share for options originally priced $10.21-$15.21.
- Repricing conditional on continued employment through September 19, 2026.
- CEO Panna Sharma's 2025 total compensation: $763,750.
- CFO David R. Margrave's 2025 total compensation: $585,580.
- CSO Kishor G. Bhatia's 2025 total compensation: $244,424.
- Total shares outstanding as of April 17, 2026: 11,304,697.
- CEO Panna Sharma beneficially owned 5.54% of common stock.
- Biological Mimetics, Inc. beneficially owned 7.47% of common stock.
Price Impact
More from LTRN